#62024TJ0591EU Court Upholds ARYUNA Trade Mark Despite ARMUNIA Opposition
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The judgment allows the EU word mark ARYUNA to move forward for certain medical and herbal products, rejecting Sandoz’s challenge based on earlier ARMUNIA marks. The Court agreed there was no likely confusion between ARYUNA and ARMUNIA, even though the goods are in the same broad pharmaceutical class. For pharma, healthcare, and consumer health businesses, the case reinforces that similar-looking product names are not automatically blocked. Brand owners still need strong evidence and a clear confusion risk when opposing a new EU trade mark.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- The Court upheld EUIPO’s finding that ARYUNA and ARMUNIA are not likely to be confused.
- Sandoz’s challenge to the ARYUNA trade mark application was rejected.
- Evidence submitted for the first time before the Court did not change the outcome.
Obligations
What this law requires
In EU trade mark opposition proceedings under Article 8(1)(b) of Regulation (EU) 2017/1001, refusal based on an earlier mark requires a demonstrated likelihood of confusion between the marks; similarity of goods in Class 5 alone is not sufficient.
The General Court upheld EUIPO’s conclusion that the EU word mark ARYUNA could proceed because there was no likelihood of confusion with the earlier ARMUNIA marks for the listed medical and herbal products.